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ABSTRACT
INTRODUCTION: The aim of the present study was to assess the adverse events developing in patients treating 
with intravenous(iv) tramadol to provide moderate to severe pain control in emergency department (ED) and 
to investigate the association of these adverse events with age, sex and vital signs and to compose a set of 
rules for the identification of patients in the risk group. 
MATERIAL AND METHODS: In this prospective cohort study, patients older than 18 years, admitted to ED 
during a 1-year period and administered iv tramadol were included in a secondary care public hospital. 
Information about age, sex, vital signs and adverse events were recorded. Patients defined as group 1 or 
group 2 with respect to adverse event development status and the groups were compared in terms of age, 
sex and vital signs.
RESULTS: A total of 408 patients were included in the study. Adverse events ratio after treatment was 21.1%. 
Adverse events were nausea, dizziness and vomiting. The age and the pulse rate per minute of the patients 
in group 1 were found to be higher and systolic blood pressure (SBP) was found to be lower than the pa-
tients in group 2.
CONCLUSİONS: The risk of adverse events development is higher in patients who are hypotensive, tachycardic 
and older than 56 years. Multicenter, prospective studies with larger patient groups are needed to support 
our results. 
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INTRODUCTION
Pain constitutes of approximately half of the admis-
sions to the emergency department (ED) and is count-
ed for the most frequent cause of admissions [1, 2]. 
A policy includes key points in pain management 
has been published by the American College of 
Emergency Physicians [3]. However optimal pain 
management is still controversial.
Opioids are the options of medication in pa-
tients with moderate to severe pain in ED [4]. 
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Tramadol has been suggested as an option for 
treatment of severe pain of any cause; renal col-
ic, dental problems, migraine, musculoskeletal 
disorders and such. According to the Institute for 
safe medication practice, opioids are considered 
as high-risk drugs and opioid-related medication 
errors can have serious consequences [5]. Safety 
is an important issue, especially during opioid 
therapy. Common side effects such as nausea 
and vomiting may prolong the duration of the 
patient’s stay in the ED. Moreover, rare but se-
rious side effects such as respiratory depression 
are the reasons for important morbidity and even 
death.The incidence of adverse effects depends 
on the dose and the mode of administration [6].
These drugs are most frequently given by oral and 
parenteral routes, it can be given rectally, epidur-
ally and can be added to local anaesthetics for 
peripheral nerve blockade [7, 8]. Intravenous (iv) 
route is associated with more frequent adverse 
effect than subcutaneous (sc) and intramuscu-
larly (im) route. Therefore, it is essential that 
emergency physicians have knowledge of appro-
priate patient selection and doses in EDs where 
these drugs are usually administered as iv route. 
Because there are also some clinical situations or 
patients’ group where pain management is more 
problematic. While the aim of the acute pain 
management should be delivering effective pain 
relief, assessing its ‘effectiveness’ must be taken 
into account not only a patients pain scores but 
also adverse events that might impact on patient 
outcome [9].
The aim of the present study was to assess the 
adverse events developing in patients who are treat-
ing with iv tramadol to provide moderate to severe 
pain control in ED and to investigate the association 
of these adverse events with age, sex, comorbidities 
and vital signs and to compose a set of rules for the 
identification of patients in the risk group.
MATERIALS AND METHODS
In this prospective cohort study, after the approval 
of a local ethics committee of Bitlis Eren University, 
patients older than 18 years, admitted to ED be-
tween 01.01.2018–31.12.2018 and administered 
iv tramadol were included in a secondary care public 
hospital that has approximately 150.000 patients 
admission to ED, annually. Information about age, 
sex and medication status, vital signs (blood pres-
sure, pulse, oxygen saturation) before the tramadol 
administration in triage field, time of administration, 
route of administration, whether adverse events 
were developed and if so, which adverse event was 
developed, were recorded. Patients under 18 years, 
whose data are missing in computerized system, 
pregnant patients and also patients treated with any 
other concomitant drug, to eliminate potential drug 
interactions or adverse events of any other drug, 
were excluded.
An adverse event is defined as nausea and diz-
ziness, drowsiness, fatigue, headache, increased 
sweating, vomiting, dry mouth, diarrhoea and car-
diovascular dysregulation (palpitations, tachycardia, 
postural hypotension) and serotonin syndrome, oc-
curs during the ivtramadol treatment or within the 
next 2 hours despite the correct administration of 
the drug. Patients with adverse events were defined 
as group 1 and those without adverse events were 
defined as group 2 and the groups were compared 
in terms of age, sex and vital signs.
STATISTICAL ANALYSIS
Statistical analysis was performed with the SPSS 
22.0 Statistical Package for Windows (SPSS Inc, 
Chicago, IL, USA). The median and standard de-
viation of the continuous variables were given, 
and the categorical variables were defined as per-
centages. Data were tested for normal distribution 
using the Shapiro-Wilk test. Categorical variables 
were compared with the Pearson’s Chi-Squared 
Test. Mann-Whitney U-test was used to compare 
non-continuous variables. The Receiver Operating 
Characteristics (ROC) curve was used to demon-
strate the cut-off values of age, systolic blood pres-
sure (SBP) and pulse beat. A value of p < 0.05 was 
statistically significant.
RESULTS
During the study period, a total of 1134 patients 
were administered iv tramadol. 24 of these are 
under 18 years old; 410 patients were given any 
other medication before tramadol therapy and 
292 patients whose data are missing in the system 
were excluded from the study. A total of 408 pa-
tients were included in the study. The mean age 
of the patients included in the study was 48.94 ± 
± 19.56 (16–95) and 60.8% of these were fe-
male. Mean systolic blood pressure on triage field 
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was 115.83 ± 21 (80–190); mean pulse beat was 
85.39 ± 14.54 (49–130). Adverse events ratio after 
treatment was 21.1% (n = 86). Adverse events 
were nausea in 74.4% (n = 64), dizziness in 32.6% 
(n = 28) and vomiting in 23.3% (n=20). The char-
acteristics of patients are shown in Table 1. Head 
and neck pain (30.9%) and abdominal pain (27.5%) 
were the most common cause of tramadol-treated 
patients. These were followed by waist and back 
pain (14.7%), renal colic pain (11.7%), chest pain 
(9.3%) and extremity pain (5.9%).
When patient’s characteristics are evaluated with 
respect to adverse event development status; the 
age and the pulse rate per minute of the patients in 
group 1 were found to be statistically significantly 
higher and SBP was found to be statistically signifi-
cantly lower than the patients in group 2 (p < 0.05). 
Differences between groups in terms of age and 
vital signs are shown in Table 2.
There were no differences between male and 
female with respect to adverse events development 
(p > 0.05).
The cut-off value for SBP was determined to be 
105 mmHg with respect to adverse event develop-
ment. Patients with a SBP of 105 mm Hg or less had 
an increased incidence of adverse event (45.8% vs 
7.6%). For this cut-off value, sensitivity is 76.74% 
and specificity is 75.78%. The area under the curve 
obtained in the Roc curve was 0.819 and this value 
was statistically significant (AUC: 0.819, 95% GA: 
0.735–0.903, P: 0.001).
The cut-off value for age was determined to be 
56 years in terms of adverse event development. 
Patients aged 56 years or older had an increased in-
cidence of adverse event (31.6% vs 14.4%). For this 
cut-off value, sensitivity is 41.86% and specificity is 
33.54%. The area under the curve obtained in the 
Roc curve was 0.666 and this value was statistical-
ly significant (AUC: 0.666, 95% GA: 0.562–0.769, 
P: 0.001).
The cut-off value for pulse rate was determined 
to be 90 beats/min in terms of adverse event de-
velopment. Patients with a pulse 90 beats/min or 
higher had an increased incidence of adverse event 
(30.5% vs 12.8%). For this cut-off value, sensitivity 
is 32,56% and specificity is 40.99%. The area under 
the curve obtained in the Roc curve was 0.641 and 
this value was statistically significant (AUC: 0.641, 
95% GA: 0.545–0.737, P: 0.005).
The comparison of groups in terms of age, SBP 
and pulse rate are shown in Table 3.
Table 1. The characteristics of participants 
(n = 408)
Min-max Average ± SD
Age (years) 16–95 48.94 ± 19.56 
(48)
SBP (mm Hg) 80–190 115.83 ± 21.00 
(110)
DBP (mm Hg) 50–110 72.84 ± 12.31 
(70)
Pulse ( /min) 49–130 85.39 ± 14.54 
(87)
Saturation (%) 84–99 95.26 ± 2.86 
(96)
N %
Sex Female 248 60.8
Male 160 39.2
Adverse events 
development
Group 1 86 21.1
Group 2 322 78.9
Adverse events 
(n = 86)
Nause 64 74.4
Vomiting 20 23.3
Dizziness 28 32.6
SBP — systolic blood pressure; DBP — diastolic blood pressure
Table 2. The comparison of groups with respect to age and vital signs
Adverse event
Z-value P-valueGroup 2 (n = 322) Group 1 (n = 86)
Average ± SD Average ± SD
Age (years) 46.32 ± 17.82 (45) 58.74 ± 22.7 (66) -3.336 0.001**
SBP (mm Hg) 120.19 ± 19.92 (120) 99.53 ± 16.61 (90) -6.500 0.001**
DBP (mm Hg) 75.34 ± 12.09 (70) 63.49 ± 7.83 (60) -6.282 0.001**
Pulse (/min) 84.17 ± 13.83 (86) 89.98 ± 16.34 (94) -2.843 0.004**
Oxygen saturation (%) 95.16 ± 2.86 (96) 95.65 ± 2.85 (97) -1.231 0.218
SBP — systolic blood pressure; DBP — diastolic blood pressure, Z — Mann -Whitney U Test, **p < 0.01
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DISCUSSION
Opioid reliability-related debates are still common 
about patients in ED and it is required reliable data 
on opioid efficacy and safety in ED patients. Unfor-
tunately, randomized controlled trials and studies 
have focused on classical opioids, especially mor-
phine and its derivatives. In studies in the literature, 
the reported incidence of tramadol adverse events is 
highly variable. Niemi-Murola et al. reported a wide 
range of opioid-related short-term adverse events, 
ranging from 4%–46% due to small sample size, in 
a review of the adverse events of opioid agents that 
are given in ED setting in 2011 [10]. In a retrospec-
tive study that is involving 31.742 patients, Daoust 
et al. reported that all adverse event incidence is 
5.9% and the most common adverse events are 
nausea-vomiting, hypotension, and desaturation 
[11]. Cepeda et al reported that the incidence of 
all adverse events was 8%; reported nausea and 
vomiting rate of 26% and a respiratory depression 
incidence of 1.5% [12].
In this study, the rate of patients who developed 
adverse event after treatment was 21.1%; the ad-
verse events were 74.4% of nausea, 32.6% of dizzi-
ness and 23.3% of vomiting.Variable numbers were 
included in the literature, but the incidence of ad-
verse events was higher than most studies. In these 
studies, However, if major adverse event rates such 
as respiratory depression and minor adverse events 
such as nausea and vomiting were evaluated sepa-
rately, it is seen that the adverse event rates of minor 
adverse events were similar, even lower, to those of 
our study [12]. In this study, there were no patients 
with any major adverse event. One reason for this is 
that the drug had not already been administered to 
patients who were hypotensive, desaturate, allergic 
persons, after the pre-evaluation of the relevant 
physician, as the common opioid side effects were 
well-known. The frequency and rate of developing 
adverse events are in accordance with the short-
term adverse events reported in the literature.
In addition, opioid-related adverse event devel-
opment is affected by many factors. For example, 
female patients are more likely to have nausea and 
vomiting; elderly patients are less prone to vomiting 
and developing more respiratory depression [13–15]. 
A study conducted in 2015, it is reported that more 
adverse events in the female gender, patients old-
er than 65 years, patients receiving medication 
via iv route and patients with chronic obstructive 
pulmonary disease (COPD) [11]. Similarly, there 
are studies reporting that the incidence of adverse 
events, especially nausea and vomiting are higher 
in females in the literature [18, 19]. Many studies 
have reported that females have more numerous 
and frequent pain and more chronic symptoms than 
men [16]. In our study, there was no statistically 
significant difference in adverse event development 
in terms of gender. This may be due to changes in 
socialization and social rules, the frequency of abuse 
and trauma, or the frequency of depressive and 
anxiety disorders.
Several studies have supported that the incidence 
of adverse events in elderly patients is higher than 
younger patients [10–13]. Cepeda et al. reported 
that the incidence of adverse events increased as 
the age increased, at the same time the risk of res-
piratory depression increased, and the risk of nausea 
and vomiting decreased in their studies in which 
8855 patients were evaluated [12]. It is reported 
that more frequently hypotension is developed in 
patients older than 65 years in another study [11]. 
Table 3. The comparison of groups with respect to age, systolic blood pressure and pulse rate.
Adverse event
χ² pGroup 2 (n = 322) Group 1 (n = 86)
N(%) N(%)
Age (years) < 56 years 214 (85.6%) 36 (14.4%) 7.649 0.006**
≥ 56 years 108 (68.4%) 50 (31.6%)
SBP (mm Hg) ≤ 105 mm Hg 78 (54.2%) 66 (45.8%) 38.722 0.001**
> 105 mm Hg 244 (92.4%) 20 (7.6%)
Pulse (/min) < 90/min 190 (87.2%) 28 (12.8%) 8.507 0.004**
≥ 90/min 132 (69.5%) 58 (30.5%)
SBP — sistolic blood pressure; χ² — Continuity (Yates) correction; **p < 0.01
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There was a single randomized controlled trial in 
which only patients older than 65 years were as-
sessed, which is the result of a lower rate of adverse 
events than other studies in the literature [17]. This 
lower rate of adverse events is attributed to the ad-
ministration of opioid analgesics in half dose. Sim-
ilar to the literature, in our study, the incidence of 
adverse events increases as age increases. Increased 
adverse events can be explained with decreased 
clearance of opioids, prolongation of elimination 
half-life and low distribution volume, namely phar-
macokinetic differences in the elderly [12]. However, 
unlike the literature, the cut-off value for age was 
found to be 56 in our study. This can be attribut-
ed to the low age-average of the participants of 
the study.
In the literature, in the ED setting, there were no 
studies investigating the relationship between vital 
signs and adverse events development in patients 
receiving iv tramadol. Only in a study conducted in 
2015, that were evaluated adverse events of opioid 
agents, it is reported that tachycardic patients had 
more frequently hypotension. However, no cut-off 
pulse rate is mentioned in this study, and this ad-
verse event is not especially worked on the tramadol 
[11]. In this study, patients with lower SBP than 
105 mm Hg and higher pulse rate than 90 beats 
per minute were more likely to develop adverse 
events. The more frequently adverse event devel-
opment in tachycardic patients is consistent with 
the literature.
STUDY LIMITATIONS
The first limitation of this study is that the authors 
do not have information on whether the drug is 
administered at the optimal dose since the patient’s 
weight is not known. Another limitation is that 
adverse events following drug administration are 
recorded only according to patient’s symptoms. De-
tecting changes in vital signs by re-recording vital 
findings may be a separate study topic.
CONCLUSION
In this study, it was aimed to identify a set of rules 
that could be used in predicting adverse event de-
velopment in patients who are given iv tramadol 
treatment in emergency setting. The incidence of 
adverse events was found to be statistically signif-
icantly higher in patients older than 56 years of 
age, patients with a SBP of 105 mm Hg or less and 
patients with a pulse rate 90 beats/min or higher. 
Multi-centre, prospective studies with larger patient 
groups are needed to support these results.
funding and support: None.
Conflict of interest: All authors declare that they 
have no conflict of interest.
Ethical approval: All procedures performed in 
studies involving human participants were in 
accordance with the ethical standards of the 
institutional and/or national research committee 
and with the 1964 Helsinki declaration and its later 
amendments or comparable ethical standards. This 
article does not contain any studies with animals 
performed by any of the authors.
RefeRences
1. Cordell WH, Keene KK, Giles BK, et al. The high prevalence of pain in 
emergency medical care. Am J Emerg Med. 2002; 20(3): 165–169, 
doi: 10.1053/ajem.2002.32643, indexed in Pubmed: 11992334.
2. Grenman D, Niemi-Murola L, Kalso E. Management of pain in a sur-
gical emergency unit—Underlying factors affecting its delivery. Acute 
Pain. 2008; 10(3-4): 137–144, doi: 10.1016/j.acpain.2008.05.013.
3. Pain management in the emergency department. Annals of 
Emergency Medicine. 2004; 44(2): 198, doi: 10.1016/j.anne-
mergmed.2004.04.003.
4. Smith MD, Wang Y, Cudnik M, et al. The effectiveness and ad-
verse events of morphine versus fentanyl on a physician-staffed 
helicopter. J Emerg Med. 2012; 43(1): 69–75, doi: 10.1016/j.
jemermed.2011.05.018, indexed in Pubmed: 21689900.
5. Institute for Safe Medication Practices. ISMP’s list of high alert medi-
cations. https://ismp.org/Tools/highalertmedications.pdf (29.06.2010).
6. Barkin RL. Extended-release Tramadol (ULTRAM ER): a pharmacothera-
peutic, pharmacokinetic, and pharmacodynamic focus on effectiveness 
and safety in patients with chronic/persistent pain. Am J Ther. 2008; 
15(2): 157–166, doi: 10.1097/MJT.0b013e31815b035b, indexed in 
Pubmed: 18356636.
7. Wu CL, Naqibuddin M, Fleisher LA. Measurement of patient satisfac-
tion as an outcome of regional anesthesia and analgesia: a systematic 
review. Reg Anesth Pain Med. 2001; 26(3): 196–208, doi: 10.1053/
rapm.2001.22257, indexed in Pubmed: 11359218.
8. Schug SA. Patient satisfaction--politically correct fashion of the 
nineties or a valuable measure of outcome? Reg Anesth Pain Med. 
2001; 26(3): 193–195, doi: 10.1053/rapm.2001.21433, indexed in 
Pubmed: 11359217.
9. Wu CL, Hurley RW, Anderson GF, et al. Effect of postoperative epidural 
analgesia on morbidity and mortality following surgery in medicare 
patients. Reg Anesth Pain Med. 2004; 29(6): 525–33; discussion 515, 
indexed in Pubmed: 15635510.
Eylem Kuday Kaykısız et al., Adverse events with tramadol treatment in ED
97www.journals.viamedica.pl
10. Niemi-Murola L, Unkuri J, Hamunen K. Parenteral opioids in emergency 
medicine — A systematic review of efficacy and safety. Scand J Pain. 
2011; 2(4): 187–194, doi: 10.1016/j.sjpain.2011.05.008, indexed in 
Pubmed: 29913751.
11. Daoust R, Paquet J, Lavigne G, et al. Impact of age, sex and route of 
administration on adverse events after opioid treatment in the emer-
gency department: a retrospective study. Pain Res Manag. 2015; 20(1): 
23–28, doi: 10.1155/2015/316275, indexed in Pubmed: 25664538.
12. Cepeda MS, Farrar JT, Baumgarten M, et al. Side effects of opioids 
during short-term administration: effect of age, gender, and race. 
Clin Pharmacol Ther. 2003; 74(2): 102–112, doi: 10.1016/S0009-
9236(03)00152-8, indexed in Pubmed: 12891220.
13. Bijur PE, Esses D, Birnbaum A, et al. Response to morphine in male 
and female patients: analgesia and adverse events. Clin J Pain. 2008; 
24(3): 192–198, doi: 10.1097/AJP.0b013e31815d3619, indexed in 
Pubmed: 18287823.
14. Zun LS, Downey LaV, Gossman W, et al. Gender differences in narcot-
ic-induced emesis in the ED. Am J Emerg Med. 2002; 20(3): 151–154, 
doi: 10.1053/ajem.2002.32631, indexed in Pubmed: 11992331.
15. Cepeda MS, Farrar JT, Baumgarten M, et al. Side effects of opioids 
during short-term administration: effect of age, gender, and race. 
Clin Pharmacol Ther. 2003; 74(2): 102–112, doi: 10.1016/S0009-
9236(03)00152-8, indexed in Pubmed: 12891220.
16. Barsky AJ, Peekna HM, Borus JF. Somatic symptom reporting in 
women and men. J Gen Intern Med. 2001; 16(4): 266–275, indexed 
in Pubmed: 11318929.
17. Chang AK, Bijur PE, Gallagher EJ. Randomized clinical trial comparing 
the safety and efficacy of a hydromorphone titration protocol to usual 
care in the management of adult emergency department patients 
with acute severe pain. Ann Emerg Med. 2011; 58(4): 352–359, 
doi: 10.1016/j.annemergmed.2011.03.003, indexed in Pubmed: 
21507527.
